• Title/Summary/Keyword: Polycystic ovary syndrome

Search Result 127, Processing Time 0.02 seconds

Evaluation of Secondary Obesity (이차성 비만의 진단)

  • Kim, Bo-Yeon
    • Archives of Obesity and Metabolism
    • /
    • v.1 no.2
    • /
    • pp.53-58
    • /
    • 2022
  • While the rising epidemic of obesity is primarily attributed to a sedentary lifestyle, poor dietary habits, and the aging of the population, secondary causes of obesity generally go undetected and untreated. These include endocrinological disorders, such as Cushing's syndrome, polycystic ovary syndrome, hypothalamic obesity, hypogonadism, and hypothyroidism, as well as genetic, syndromic, and drug-related obesity. We present an overview of the major disorders associated with obesity, highlighting the pathophysiologic mechanisms and discussing the diagnostic and treatment strategies that are most helpful to practicing physicians in recognizing and treating these generally under-detected and undertreated disorders.

Clinical outcomes of three- or five-day treatment with clomiphene citrate combined with gonadotropins and a timed intercourse cycle in polycystic ovary syndrome patients

  • Bae, Sung-Ah;Joo, Jong-Kil;Choi, Jong-Ryeol;Kim, Sun-Suk;Lee, Kyu-Sup
    • Clinical and Experimental Reproductive Medicine
    • /
    • v.42 no.3
    • /
    • pp.106-110
    • /
    • 2015
  • Objective: This study aimed to investigate the effect of a new clomiphene citrate (CC) regimen on preventing thin endometrial lining in polycystic ovary syndrome (PCOS) patients receiving CC plus gonadotropin treatment with a timed intercourse cycle. Methods: A total of 114 women with PCOS were included in this trial. Patients were divided into two groups and treated in accordance with the controlled ovarian stimulation (COS) protocol. In group A, 104 COS cycles in 67 patients were included, and in each cycle 150 mg CC was given for three days, starting from day 3. In group B, 69 COS cycles in 47 patients were included, in which 100 mg CC was given for five days, starting from day 3. The thickness of the endometrium was measured on the day of human chorionic gonadotropin (hCG) injection. Timed intercourse was recommended at 24 and 48 hours after the hCG injection. Results: Additional doses of human menopausal gonadotropin and the number of days of hCG administration were not significantly different between the two groups. Endometrial thickness on the day of hCG administration was significantly larger in group A than group B (4$9.4{\pm}2.1mm$ vs. $8.5{\pm}1.7mm$, p=0.004). The pregnancy rate was significantly higher in group A than in group B (38.4% vs. 21.7%, p=0.030). Conclusion: Three-day CC treatment resulted in a significantly higher pregnancy rate than the standard five-day CC treatment in a timed intercourse cycle in PCOS patients. Facilitating adequate endometrial growth via the early discontinuation of CC might be a crucial factor in achieving a higher pregnancy rate.

New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer

  • Liu, Ai Ling;Liao, Hong Qing;Li, Zhi Liang;Liu, Jun;Zhou, Cui Lan;Guo, Zi Fen;Xie, Hong Yan;Peng, Cui Ying
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.12
    • /
    • pp.5087-5094
    • /
    • 2016
  • mTOR, the mammalian target of rapamycin, is a conserved serine/threonine kinase which belongs to the phosphatidyl-linositol kinase-related kinase (PIKK) family. It has two complexes called mTORC1 and mTORC2. It is well established that mTOR plays important roles in cell growth, proliferation and differentiation. Over-activation of the mTOR pathway is considered to have a relationship with the development of many types of diseases, including polycystic ovary syndrome (PCOS) and ovarian cancer (OC). mTOR pathway inhibitors, such as rapamycin and its derivatives, can directly or indirectly treat or relieve the symptoms of patients suffering from PCOS or OC. Moreover, mTOR inhibitors in combination with other chemical-molecular agents may have extraordinary efficacy. This paper will discuss links between mTOR signaling and PCOS and OC, and explore the mechanisms of mTOR inhibitors in treating these two diseases, with conclusions regarding the most effective therapeutic approaches.

Molecular Variants of the $LH{\beta}$-subunit in Infertile Patients with Polycystic Ovary Syndrome (PCOS) in Korean Women (한국인의 다낭성 난포증후군 불임환자에서 황체형성 호르몬 유전자의 분자변이 연구)

  • Kim, Nam-Keun;Chung, Hyung-Min;Lee, Eu-Gene;Nam, Yoon-Sung;Choi, Dong-Hee;Sohn, Tae-Jong;Lee, Sook-Hwan;Ko, Jung-Jae;Cha, Kwang-Yul
    • Clinical and Experimental Reproductive Medicine
    • /
    • v.27 no.2
    • /
    • pp.173-177
    • /
    • 2000
  • 연구목적: 한국여성의 다낭성 난포증후군 환자에서 황체형성 호르몬 exon 2 유전자의 변이를 탐색하여 이들 변이와 질환과의 관련성 여부를 밝히고자 하였다. 연구재료 및 방법: 21명의 다낭성 난포증후군 환자를 대상으로 황체형성 호르몬 exon 2(Trp8Arg;TGG to CGG and Ile15Thr; ATC to ACC)의 변이를 탐색하였다. 혈액에서 Genomic DNA를 추출하여 PCR로 증폭한 후 RFLP 방법으로 변이형을 구분하였다. 결과: 황체형성 호르몬 exon 2의 변이형이 다낭성 난포증후군 환자에서 28.6%로 이미 조사된 바 있는 대조군의 16.7% 보다 약간 높게 나타났으나 통계적으로 유의한 차이는 없었다(p>0.05). 결론: 황체형성 호르몬 exon 2의 변이가 한국인의 다낭성 난포증후군 발병과 관련이 있는지를 밝히기 위해 더 많은 개체에 대한 연구가 요구된다.

  • PDF

A Study on Oriental Medicine Diagnostic Application through Analysis of Digital Infrared Thermographic Imaging In Polycystic Ovary Syndrome Females (다낭성 난소 증후군 여성의 DITI 특성 분석을 통한 한의학적 진단 활용성에 관한 연구)

  • Kim, Eun-Gyung;Lee, Mi-Joo;Hwang, Deok-Sang;Lee, Chang-Hoon;Lee, Kyung-Sub
    • Journal of Oriental Medical Thermology
    • /
    • v.8 no.1
    • /
    • pp.18-25
    • /
    • 2010
  • Purpose : This study was performed to compare the characteristics of digital infrared thermographic imaging(DITI) in polycystic ovary syndrome(PCOS) patients with regulary cycling controls. Methods : We studied 19 patients visiting ${\bigcirc}{\bigcirc}$ korean hospital from 7th May 2010 to 8th January 2011. The subjects were categorized in two groups. 8 PCOS patients and 11 healthy regularly cycling controls. We investigated the difference of DITI between two groups by Mann-Whitney U-test using SPSS for window (version 17.0). Results : The average temperatures of five points(In-dang(EX-HN3), GV4, GV6, GV12, GV17) between PCOS and non-PCOS groups showed a little difference though p-value is not less than 0.05. The DITI differences of PCOS group between In-dang and thorax or between In-dang and abdomen showed lower than those of non-PCOS group though not a statistical significant level. Conculsion : The results suggest that DITI differences between PCOS and non-PC OS groups need to be developed to some degree for the diagnosis tool of PCOS.

  • PDF

Literature Review of Clinical Studies for the Relationship between Ultrasonographic Examination and Syndrome Differentiation Classification in Chinese Medicine (초음파영상검사와 한의변증분류와의 관계와 관련된 중의학 임상연구에 대한 문헌고찰)

  • Hwang, Ji Hye;Ko, Dongkun
    • Journal of Physiology & Pathology in Korean Medicine
    • /
    • v.32 no.4
    • /
    • pp.217-225
    • /
    • 2018
  • This study was to investigate the relationship between ultrasonographic examination and pattern identification classification on cinical studies in chinese medicine. We searched clinical studies related correlation between ultrasonographic examination and pattern identification classification in chinese medicine, that published from 2013 to 2016 in China National Knowledge Infrastructure (CNKI) databases by keywords, 'ultrasound(超?)', 'chinese medicine(中?)', 'syndrome differentiation (辨?)'. Seventeen studies were found. There were 7 studies of gynecological diseases including polycystic ovary syndrome and uterine myoma, 5 studies of fatty liver, 3 studies of arthritis, and 1 studie of thyroid nodule and lymphadenopathy respectively. As a result, ii is thought that there was a certain degree of correlation between the change of the ultrasonographic image and the pathological types according to traditional chinese medicine (TCM) syndrome differentiation and ultrasonographic examination could be used as secondary means for the TCM syndrome differentiation classification. In conclusion, by using ultrasonograph device in a medicinal way of TCM and traditional korean medicine (TKM), it is thought that more detailed and accurate diagnosis and treatment are possible and the evidence for reasonableness of syndrome differentiation in TCM and TKM its validity can be secured.

The Analysis of SHP (Small Heterodimer Partner) Gene Mutation in Infertile Patients with Polycystic Ovary Syndrome (PCOS) in Korea (한국인 다낭성 난포증후군 환자에서 SHP 유전자 변이 분석)

  • Lee, Su-Man;Choi, Hueng-Sik;Lee, Sook-Hwan;Han, Jung-Hee;Nam, Bo-Hyun;Kwak, In-Pyung;Nam, Yoon-Sung;Kim, Nam-Keun;Lee, Kyo-Won;Jeon, Hye-Sun
    • Clinical and Experimental Reproductive Medicine
    • /
    • v.28 no.2
    • /
    • pp.141-145
    • /
    • 2001
  • Objective: We inversigated Small Heterodimer Partner (SHP) gene mutation in Korean Polycystic Ovarian Syndrome (PCOS) patients. SHP protein regulates the activity of nuclear receptors which regulate the cellular development and differentiation. Recently, the mutation of SHP gene was found in the obesity and diabetes patients in Japanese group, and suggested that its mutation may involved in pathogenic mechanism of PCOS. Methods: This study was performed in 20 PCOS patients and 20 normal women. The DNAs were extracted from the peripheral bloods, and amplified at each exon (1 and 2) of SHP gene by PCR method. Subsequently, each PCR product was digested with the restriction enzyme indicated below for studying restriction fragment length polymorphism (RFLP). After enzyme digestion, the results of RFLP were compared PCOS patients with control women to find any sequence variation. Results: We examined 9 regions of exon 1 with Msp I, Pvu II, Dde I and 3 regions of exon 2 with Pst I, Dde I. There is no heterozygous or homozygous mutation in patients and control women at these restriction sites. Conclusion: The genetic analysis at our restriction sites in the SHP gene did not show any genetic variation in Korean PCOS patients. Our PCR-RFLP analysis was not covered the entire SHP gene (68 bp/1,006 bp), we need to further analysis of the entire SHP gene.

  • PDF

Effects of Pioglitazone on Insulin Sensitivity, Ovarian Function and Intraovarian Stromal Blood Flow in Women with Polycystic Ovary Syndrome (다낭성난소증후군 환자에서 Pioglitazone이 인슐린 민감도, 난소 기능, 난소 기질 내 혈류에 미치는 영향)

  • Lee, Hyang-Ah;Kim, Chung-Hoon;Choi, Jeong-Won;Park, Sun-Jung;Lee, Soo-Jeong;Choi, Eun-Sun;Kim, Sung-Hoon;Chae, Hee-Dong;Son, Young-Soo;Kang, Byung-Moon
    • Clinical and Experimental Reproductive Medicine
    • /
    • v.32 no.2
    • /
    • pp.155-164
    • /
    • 2005
  • Objective: This study was performed to investigate the effects of pioglitazone, an insulin sensitizing agent, on insulin resistance, ovarian function and intraovarian stromal blood flow in patients with polycystic ovarian syndrome (PCOS). Material and Methods: Thirty patients with PCOS, aged 18~34 years, were recruited. Criteria for diagnosis of PCOS were as defined in 2003 Rotterdam consensus. They were treated for 6 months with pioglitazone at a dose of 30 mg/day orally. The hormonal blood profile, fasting serum glucose levels, a glycemic response to 75 g oral glucose tolerance test (OGTT), and an ovarian stromal artery (OSA) blood flow were assessed at baseline and after 6 months of treatment. Results: Eighteen (60.0%) of 30 patients treated with pioglitazone demonstrated a spontaneous ovulation After pioglitazone treatment, fasting insulin concentrations, serum glucose levels after 75 g OGTT significantly decreased (p=0.001, p=0.04, respectively), and fasting glucose to insulin (G/I) ratio significantly increased (p<0.001). The pioglitazone treatment induced a significant reduction in serum LH, testosterone (T) and free T levels (p<0.001, p=0.02, p=0.002, respectively). The resistance index (RI) values of OSA significantly increased after treatment (p<0.001). In analyzing pioglitazone-treated patients according to their body mass index (BMI), nonobese group as well as obese group showed a significant improvement in fasting G/I ratio (p<0.01). The pioglitazone treatment induced a significant reduction in serum LH and free T levels in nonobese group (p<0.001, p<0.05, respectively) as well as obese group (p=0.001, p<0.05, respectively). The RI values of OSA significantly increased in both nonobese and obese groups after pioglitazone treatment (p<0.001, p=0.003, respectively). Conclusions: Pioglitazone could ameliorate the glycoinsulinemic metabolism, and this beneficial effects of this drug could improve the endocrine-reproductive condition associated with the decrease of ovarian stromal artery blood flow, in both nonobese and obese patients with PCOS.

Stereological study of the effects of letrozole and estradiol valerate treatment on the ovary of rats

  • Noorafshan, Ali;Ahmadi, Maryam;Mesbah, Seyed-Fakhroddin;Karbalay-Doust, Saied
    • Clinical and Experimental Reproductive Medicine
    • /
    • v.40 no.3
    • /
    • pp.115-121
    • /
    • 2013
  • Objective: Letrozole and estradiol valerate are used to treat some hormonally-responsive symptoms and also in modeling of the polycystic ovary syndrome. However, the stereological analysis of the ovary has received less attention. Estimation of the whole ovary volume using the Cavalieri method can be applied in any orientation desired, but estimation of the mean volume of the oocytes requires isotropic uniform random sectioning. Here, a combined method was developed for estimating the parameters. To our knowledge, no comparison has been made of the effects of letrozole and estradiol on the ovary. Methods: Sixty rats were divided into 4 groups receiving estradiol (4 mg/kg), olive oil, letrozole (1 mg/kg), or normal saline. After 21 days, their ovaries were studied. Results: Relative to the control group, the total volume of the ovary and the cortex increased in the letrozole-treated and estradiol-treated rats. In addition, the number of the preantral, antral, and granulosa cells decreased by 43% to 56% in the letrozole- and estradiol-treated rats. On average, a 19% increase was observed in the atretic oocytes of the letrozole-treated and estradiol-treated rats, but the mean oocyte volume decreased by 29% to 44% in letrozole- and estradiol-treated rats. Furthermore, the letrozole-treated rats showed a 5-fold and 7-fold increase in the volume of the cysts and corpus luteum, respectively. A 3-fold increase was found in the volume of both the cysts and corpus luteum in the estradiol group. Conclusion: The structural changes of the ovary were most pronounced in the letrozole-treated animals.